Dalriada announces strategic collaboration on iCLASS Platform with a public computational company

Dalriada, a small molecule contract research organization (CRO) focused on translationally guided drug discovery, recently announced a strategic collaboration with an undisclosed, publicly traded computational company specializing in molecular discovery to jointly advance a pipeline of first-in-class and best-in-class targeted therapeutics. Through this collaboration, Dalriada will leverage its iCLASS platform to uncover cryptic sites and identify novel chemical matter hits for a selection of high-value, challenging therapeutic targets.

The collaboration will also explore the integration of Dalriada’s proprietary live-cell, multi-proteomics approach with the collaborator’s computational technologies to evaluate synergies and accelerate drug discovery against otherwise intractable targets.

Dalriada is an alumnus of our CAAP® program and Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, and presented at the OBIO® Investment Summit.